Wharton, Sean

Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials

Rubino, D., Bjorner, J. B., Rathor, N., Sharma, A. M., von Huth Smith, L., Wharton, S., Wadden, T., Zeuthen, N., & Kolotkin, R. L. (2024) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 56

Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison

le Roux, C. W., Hankosky, E. R., Wang, D., Malik, R., Yu, M., Hickey, A., Kan, H., Bunck, M. C., Stefanski, A., Garcia‐Perez, L., et al. (2023) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 36

Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada

Wharton, S., Haase, C. L., Kamran, E., Liu, A., Mancini, J., Neish, D., Pakseresht, A., Power, G. S., & Christensen, R. A. G. (2020) · Obesity Science & Practice

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 26

Treatment with orforglipron, an oral glucagon-like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes

Wharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K. (2025) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 26

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4)

Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · Diabetologie und Stoffwechsel

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 13

1966-LB: Efficacy and Safety of Semaglutide 7.2 mg in Obesity—STEP UP Trial

WHARTON, S., FREITAS, P., HJELMESÆTH, J., KABISCH, M., KANDLER, K., LINGVAY, I., DE LOS ANGELES QUIROGA, M., ROSENSTOCK, J., & GARVEY, W. T. (. (2025) · Diabetes

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 8